UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 266

Sortiert nach

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Haematologica (Roma), 2018-02, Vol.103 (2), p.197

2018

Volltextzugriff (PDF)

Tribody [(HER2) 2 xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

Frontiers in immunology, 2018-04, Vol.9, p.814-814

2018

Volltextzugriff (PDF)

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

Blood, 2013-10, Vol.122 (18), p.3220-3229

2013

Volltextzugriff (PDF)

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

Leukemia, 2018-08, Vol.32 (8), p.1697-1712

2018

Volltextzugriff (PDF)

Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3259-3271

2013

Volltextzugriff (PDF)

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Blood, 2007-08, Vol.110 (4), p.1330-1333

2007

Volltextzugriff (PDF)

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition

Cancer research (Chicago, Ill.), 2007-02, Vol.67 (4), p.1783-1792

2007

Volltextzugriff (PDF)

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

Proceedings of the National Academy of Sciences - PNAS, 2007-06, Vol.104 (26), p.11008-11013

2007

Volltextzugriff (PDF)

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Haematologica (Roma), 2021-07, Vol.106 (7), p.1857

2021

Volltextzugriff (PDF)

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

The lancet oncology, 2014-06, Vol.15 (7), p.757-766

2014

Volltextzugriff (PDF)

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

Blood cancer journal (New York), 2019-11, Vol.9 (12), p.88-9, Article 88

2019

Volltextzugriff (PDF)

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Journal of clinical oncology, 2008-01, Vol.26 (3), p.455-462

2008

Volltextzugriff (PDF)

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

Frontiers in immunology, 2023-10, Vol.14, p.1227572-1227572

2023

Volltextzugriff (PDF)

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation

International journal of cancer, 2010-01, Vol.126 (1), p.239-246

2010

Volltextzugriff (PDF)

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

Haematologica (Roma), 2015-04, Vol.100 (4), p.541

2015

Volltextzugriff (PDF)

STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer

Scientific reports, 2017-08, Vol.7 (1), p.7976-13, Article 7976

2017

Volltextzugriff (PDF)

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

Frontiers in immunology, 2022-06, Vol.13, p.908093-908093

2022

Volltextzugriff (PDF)

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

Haematologica (Roma), 2017-02, Vol.102 (2), p.381

2017

Volltextzugriff (PDF)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

Oncoimmunology, 2018-01, Vol.7 (8), p.e1448331-e1448331

2018

Volltextzugriff (PDF)

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study

Psycho-oncology (Chichester, England), 2013-07, Vol.22 (7), p.1509-1516

2013

Volltextzugriff (PDF)

1 – 25 von 266

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

Englisch
(265)
Japanisch
(20)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(118)
Life Sciences & Biomedicine
(115)
Humans
(101)
Hematology
(58)
Female
(55)
Male
(48)
Oncology
(47)
Middle Aged
(44)
Adult
(43)
Biological And Medical Sciences
(43)
Aged
(39)
Medical Sciences
(39)
Immunology
(30)
Animals
(20)
Treatment Outcome
(20)
Adolescent
(18)
Hematologic And Hematopoietic Diseases
(17)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(17)
Mice
(17)
Tumor Cells, Cultured
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Tribody [(HER2) 2 xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)

European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells

The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation

Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study

STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial

Suchergebnisse filtern